Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07349394 · ClinicalTrials.gov registry record · Phase 1
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
A Phase 1 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT07349394 is a Phase 1 study of Cystic Fibrosis that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 18 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07349394, a Phase 1 study of Cystic Fibrosis, is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.
Conditions Studied
Interventions
- DRUG Rosuvastatin
- DRUG VNZ/TEZ/D-IVA
Study Locations (1)
Kansas
- Altasciences - Kansas City - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2026-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07349394
The ClinicalTrials.gov registry entry for NCT07349394 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (90% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT07349394 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT07349394 about?
NCT07349394 is a clinical study titled "Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants". The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.
What is the current status of trial NCT07349394?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-01-12. Estimated completion is 2026-04-04.
What conditions does trial NCT07349394 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT07349394?
The interventions under investigation include: Rosuvastatin (DRUG), VNZ/TEZ/D-IVA (DRUG).
Who is sponsoring clinical trial NCT07349394?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07349394 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.